Agonist activation of estrogen receptor beta (ERβ) sensitizes malignant pleural mesothelioma cells to cisplatin cytotoxicity
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1476-4598
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Agonist activation of estrogen receptor beta (ERβ) sensitizes malignant pleural mesothelioma cells to cisplatin cytotoxicity ; volume:13 ; number:1 ; day:2 ; month:10 ; year:2014 ; pages:1-14 ; date:12.2014
Molecular cancer ; 13, Heft 1 (2.10.2014), 1-14, 12.2014
- Klassifikation
-
Medizin, Gesundheit
- Urheber
-
Pinton, Giulia
Manente, Arcangela G.
Daga, Antonio
Cilli, Michele
Rinaldi, Maurizio
Nilsson, Stefan
Moro, Laura
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/1476-4598-13-227
- URN
-
urn:nbn:de:101:1-2019061000473170650745
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:55 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Pinton, Giulia
- Manente, Arcangela G.
- Daga, Antonio
- Cilli, Michele
- Rinaldi, Maurizio
- Nilsson, Stefan
- Moro, Laura
- SpringerLink (Online service)
Ähnliche Objekte (12)
Proteasome stress sensitizes malignant pleural mesothelioma cells to bortezomib-induced apoptosis
Chemotherapy increases CDA expression and sensitizes malignant pleural mesothelioma cells to capecitabine treatment
ADAM10 mediates malignant pleural mesothelioma invasiveness
Early detection of malignant pleural mesothelioma
KRAS signaling in malignant pleural mesothelioma
Molecular biological analysis of malignant pleural mesothelioma
Genomic Landscape of Pleural Mesothelioma and Therapeutic Aftermaths
Genomic landscape of pleural and peritoneal mesothelioma tumours
Correlation between pleural fluid cytology and magnitude of pleural invasion in patients with malignant pleural mesothelioma
Therapeutic potential of targeting S100A11 in malignant pleural mesothelioma
Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition
GAS5 long non-coding RNA in malignant pleural mesothelioma
Proteasome stress sensitizes malignant pleural mesothelioma cells to bortezomib-induced apoptosis
Chemotherapy increases CDA expression and sensitizes malignant pleural mesothelioma cells to capecitabine treatment
ADAM10 mediates malignant pleural mesothelioma invasiveness
Early detection of malignant pleural mesothelioma
KRAS signaling in malignant pleural mesothelioma
Molecular biological analysis of malignant pleural mesothelioma
Genomic Landscape of Pleural Mesothelioma and Therapeutic Aftermaths
Genomic landscape of pleural and peritoneal mesothelioma tumours
Correlation between pleural fluid cytology and magnitude of pleural invasion in patients with malignant pleural mesothelioma
Therapeutic potential of targeting S100A11 in malignant pleural mesothelioma
Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition
GAS5 long non-coding RNA in malignant pleural mesothelioma
Proteasome stress sensitizes malignant pleural mesothelioma cells to bortezomib-induced apoptosis
Chemotherapy increases CDA expression and sensitizes malignant pleural mesothelioma cells to capecitabine treatment
ADAM10 mediates malignant pleural mesothelioma invasiveness
Early detection of malignant pleural mesothelioma
KRAS signaling in malignant pleural mesothelioma
Molecular biological analysis of malignant pleural mesothelioma
Genomic Landscape of Pleural Mesothelioma and Therapeutic Aftermaths
Genomic landscape of pleural and peritoneal mesothelioma tumours
Correlation between pleural fluid cytology and magnitude of pleural invasion in patients with malignant pleural mesothelioma
Therapeutic potential of targeting S100A11 in malignant pleural mesothelioma
Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition